What's Happening?
CicadaBio, a biotechnology company, has announced new preclinical data for its investigational drug CC-18, a GLP-1/anti-ActRII dual-pathway fusion protein, at the American Diabetes Association (ADA) Scientific Sessions 2026. The data revealed significant
weight reduction and lean mass preservation in diet-induced obesity mouse models and non-human primates. CC-18 demonstrated greater weight reduction than semaglutide, a current obesity treatment, while preserving and increasing lean mass. The drug also showed a 58% lower weight regain after treatment discontinuation compared to semaglutide. In non-human primates, CC-18 sustained weight reduction and favorable body composition changes, with potential for monthly dosing due to prolonged pharmacodynamic activity.
Why It's Important?
The development of CC-18 is significant as it addresses a critical challenge in obesity treatment: achieving weight loss while preserving muscle mass. Current GLP-1-based therapies often result in a reduction of lean body mass, which is crucial for metabolic health and long-term weight maintenance. By preserving muscle mass, CC-18 could improve physical function and support durable weight loss outcomes. This advancement could redefine obesity treatment, moving beyond first-generation therapies to focus on high-quality weight loss and improved body composition. The potential for extended dosing intervals also suggests a more convenient treatment regimen for patients.
What's Next?
CC-18 is advancing in clinical development, supported by Lilly’s Catalyze360 initiative, which aids in clinical proof-of-concept activities. The next steps involve further clinical trials to validate the preclinical findings and assess the drug's efficacy and safety in humans. If successful, CC-18 could become a leading treatment option for obesity, offering a novel approach that combines weight loss with muscle preservation. The biotechnology community and healthcare providers will be closely monitoring the progress of these trials, as the outcomes could influence future obesity treatment protocols.
